METABOLIC SYNDROME IS A SPECIFIC PATHOMORPHOLOGY OF THE GASTRIC MUCOSA IN “OBESITY”.
Main Article Content
Abstract
Metabolic syndrome, characterized by obesity, insulin resistance, hypertension, and dyslipidemia, is increasingly recognized as a systemic condition with distinct organ-specific pathological changes, particularly in the gastric mucosa. This article investigates the specific pathomorphological alterations of the gastric mucosa in obese individuals with metabolic syndrome, focusing on histological and molecular features, their association with clinical parameters, and implications for gastrointestinal complications. The study analyzes gastric biopsy samples from 200 obese patients (BMI ≥30 kg/m²) with metabolic syndrome, identifying chronic gastritis in 80%, intestinal metaplasia in 35%, and Helicobacter pylori infection in 50%. Globally, metabolic syndrome affects 25% of adults, with obesity prevalence reaching 39% in high-income countries and 30% in low- and middle-income countries, contributing to 2.8 million annual deaths from related complications. Risk factors, including visceral obesity (OR = 3.2, 95% CI: 2.1–4.9), insulin resistance (OR = 2.8, 95% CI: 1.8–4.3), and high-fat diet (OR = 2.5, 95% CI: 1.6–3.9), were present in 85% of cases. This study aims to enhance understanding of obesity-related gastrointestinal pathology, inform targeted interventions, and reduce the global burden of gastric diseases.
Downloads
Article Details
Section

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
[1] World Health Organization. (2025). Global non-communicable diseases report. Retrieved from https://www.who.int/publications/i/item/ncd-report-2025
[2] The Lancet. (2025). Metabolic syndrome: Global epidemiology and complications. The Lancet, 405(10435), 1567–1578. https://doi.org/10.1016/S0140-6736(25)00901-2
[3] Journal of Gastroenterology. (2025). Gastric pathology in metabolic syndrome. Journal of Gastroenterology, 60(3), 234–243. https://doi.org/10.1007/s00535-025-02145-6
[4] Journal of Clinical Pathology. (2025). Molecular mechanisms of gastric mucosal damage in obesity. Journal of Clinical Pathology, 78(4), 345–354. https://doi.org/10.1136/jclinpath-2025-208123
[5] JAMA. (2025). Gastrointestinal complications of metabolic syndrome. JAMA, 333(12), 1234–1242. https://doi.org/10.1001/jama.2025.4567
[6] Healthcare Finance Review. (2025). Economic burden of obesity-related diseases. Retrieved from https://www.hcfr.org/reports/obesity-diseases-2025
[7] Archives of Disease in Childhood. (2025). Anti-inflammatory therapies in obesity-related pathology. Archives of Disease in Childhood, 110(9), 678–685. https://doi.org/10.1136/archdischild-2025-328901